» Articles » PMID: 19432885

Combination of Peritumoral Mast Cells and T-regulatory Cells Predicts Prognosis of Hepatocellular Carcinoma

Overview
Journal Cancer Sci
Specialty Oncology
Date 2009 May 13
PMID 19432885
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

The peritumoral inflammatory environment is critical for the progression of intrahepatic recurrence of hepatocellular carcinoma (HCC) after curative resections. Here, we investigated the relevance of peritumoral mast cells (MCs) to HCC outcomes. Peritumoral tryptase(+) MCs in addition to Foxp3(+) T-regulatory cells (Tregs) were evaluated using immunohistochemistry enumeration in tissue microarrays containing 207 randomly selected HCC patients. Clinicopathological factors and postoperative outcomes were compared between high and low subgroups of MCs or Tregs. Compared to low denstiy, higher peritumoral MCs were associated with poorer clinical outcomes, and independently related to elevated 5-year recurrence incidence (54.1%vs 39.2%, P = 0.026). High-dense MCs were especially related to increased probability of early recurrence (within 2 years) (P = 0.004). We also found that peritumoral Tregs were positively correlated with MCs in density (r = 0.353, P < 0.001) and reversely related to HCC outcomes. Notably, MCs in combination with Tregs displayed better prognostic performances than MCs alone (area under curve [AUC](survival) = 0.629 vs 0.589, AUC(recurrence) = 0.632 vs 0.591). Moreover, MCs were positively correlated to alanine aminotransferase, a serum inflammatory marker (P = 0.014). Therefore, peritumoral MCs are promising prognostic parameters for HCC mainly through inflammation response-related mechanisms, and we propose that MCs and Tregs may cooperate with each other and result in poorer prognosis.

Citing Articles

AREG Upregulation in Cancer Cells via Direct Interaction with Cancer-Associated Fibroblasts Promotes Esophageal Squamous Cell Carcinoma Progression Through EGFR-Erk/p38 MAPK Signaling.

Nakanishi T, Koma Y, Miyako S, Torigoe R, Yokoo H, Omori M Cells. 2024; 13(20.

PMID: 39451251 PMC: 11506648. DOI: 10.3390/cells13201733.


Significance of Immune and Non-Immune Cell Stroma as a Microenvironment of Hepatocellular Carcinoma-From Inflammation to Hepatocellular Carcinoma Progression.

Baj J, Kolodziej M, Kobak J, Januszewski J, Syty K, Portincasa P Int J Mol Sci. 2024; 25(19).

PMID: 39408564 PMC: 11475949. DOI: 10.3390/ijms251910233.


The regulatory role and mechanism of mast cells in tumor microenvironment.

Ligan C, Ma X, Zhao S, Zhao W Am J Cancer Res. 2024; 14(1):1-15.

PMID: 38323271 PMC: 10839313.


Prognostic role of macrophages and mast cells in the microenvironment of hepatocellular carcinoma after resection.

Ali E, cervenkova L, Palek R, Ambrozkiewicz F, Hosek P, Daum O BMC Cancer. 2024; 24(1):142.

PMID: 38287290 PMC: 10823625. DOI: 10.1186/s12885-024-11904-8.


Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells.

Gao X, Zuo S Clin Exp Med. 2023; 23(6):1881-1899.

PMID: 36773210 PMC: 10543580. DOI: 10.1007/s10238-023-01015-2.


References
1.
Gallimore A, Godkin A . Regulatory T cells and tumour immunity - observations in mice and men. Immunology. 2007; 123(2):157-63. PMC: 2433304. DOI: 10.1111/j.1365-2567.2007.02748.x. View

2.
Terada T, Matsunaga Y . Increased mast cells in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Hepatol. 2000; 33(6):961-6. DOI: 10.1016/s0168-8278(00)80129-4. View

3.
Lampiasi N, Azzolina A, Montalto G, Cervello M . Histamine and spontaneously released mast cell granules affect the cell growth of human hepatocellular carcinoma cells. Exp Mol Med. 2007; 39(3):284-94. DOI: 10.1038/emm.2007.32. View

4.
Metz M, Grimbaldeston M, Nakae S, Piliponsky A, Tsai M, Galli S . Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev. 2007; 217:304-28. DOI: 10.1111/j.1600-065X.2007.00520.x. View

5.
Schepke M, Roth F, Fimmers R, Brensing K, Sudhop T, Schild H . Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol. 2003; 98(5):1167-74. DOI: 10.1111/j.1572-0241.2003.07515.x. View